<div id="readability-page-1"><div> <h2>Key Points</h2><ul><li>The company is slowly recovering from recent headwinds. </li><li>It could perform well through the next five to 10 years.</li><li>10 stocks we like better than Regeneron Pharmaceuticals ›</li></ul>Regeneron (NASDAQ: REGN) has encountered several headwinds over the past two years, including the loss of patent exclusivity for one of its growth drivers, Eylea, a medicine for wet age-related macular degeneration. Even as its long-term returns remain solid, the stock has not performed particularly well over the last 24 months. There are several reasons why Regeneron could bounce back -- in fact, it has already begun to do so, with its shares up 35% over the past six months. But does the biotech have what it takes to crush the market over the long run and turn average investors into multimillionaires?Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an &#34;Indispensable Monopoly&#34; providing the critical technology Nvidia and Intel both need. Continue »<img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-dXJsPWh0dHBzOi8vZy5mb29sY2RuLmNvbS9lZGl0b3JpYWwvaW1hZ2VzLzg2MjA5Ny9wZXJzb24tcmFpc2luZy10d28tZmlzdHMtaW4tdGhlLWFpci5qcGcmdz03MDA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="700" height="369" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-dXJsPWh0dHBzOi8vZy5mb29sY2RuLmNvbS9lZGl0b3JpYWwvaW1hZ2VzLzg2MjA5Ny9wZXJzb24tcmFpc2luZy10d28tZmlzdHMtaW4tdGhlLWFpci5qcGcmdz03MDA"/>Image source: Getty Images. <h2>What the medium term looks like</h2>Over the next five years, Regeneron's performance will depend on several assets. First, its most important product, Dupixent, a medicine for eczema and several other conditions, including COPD. This therapy should still record sales growth through the early 2030s. Second, although Eylea lost patent exclusivity, Regeneron earned approval for a high-dose (HD) formulation of the drug that comes with a friendlier dosing schedule.As Eylea HD attracts many of the old version's patients, top-line growth could improve. Third, Regeneron could make significant progress with its pipeline. Notably, the company is working on a gene therapy for genetic hearing loss, which it could launch within the next few years, provided data from clinical trials is strong enough. This would be a nice addition to Regeneron's portfolio and would further boost sales growth. However, the company's most important pipeline candidates right now might be its weight loss products. Regeneron is working on two approaches to the weight loss market. One of its candidates is a GLP-1 medicine that recently performed well in a phase 3 study in China. The other is being developed for use alongside GLP-1 therapies to help maintain lean mass as patients lose weight -- since much of the weight they shed is from muscle, which can cause issues. Regeneron's strategy could make it a notable player in the rapidly growing weight loss market. <h2>What about the long-term?</h2>For a drugmaker to achieve significantly above-average returns, it's essential to consistently innovate, launch new products, and overcome patent cliffs. Regeneron is showing that it has the means to do that. It is bouncing back nicely after losing patent exclusivity for Eylea. However, doing so over two or three decades -- what it would likely have to pull off to generate the returns needed to turn average investors into multimillionaires -- is a different story. And with a market cap of $79 billion, it's highly unlikely that Regeneron can register even better performances than it did in the past (its performance more or less matches that of the S&amp;P 500 over the past 35 years), when it was a smaller biotech company whose stock price was much more sensitive to significant clinical or regulatory milestones. So, is Regeneron a multimillionaire-maker? My view is that, like most stocks, it isn't. However, it can still deliver respectable returns over the next decade (and perhaps beyond). <h2>Should you buy stock in Regeneron Pharmaceuticals right now?</h2> Before you buy stock in Regeneron Pharmaceuticals, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Regeneron Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $497,659!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,095,404!* Now, it’s worth noting Stock Advisor’s total average return is 912% — a market-crushing outperformance compared to 185% for the S&amp;P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of March 27, 2026. Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Regeneron Pharmaceuticals. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. </div></div>

IBBQ

Regeneron Pharmaceuticals is recovering from recent challenges, with a potential for solid performance over the next five to ten years. Despite past struggles, including the loss of patent exclusivity for Eylea, the stock has seen a 35% increase in the last six months. Key products like Dupixent and new developments in weight loss therapies could drive growth. However, achieving significant long-term returns may be challenging due to its current market cap. Analysts suggest considering other stocks for potentially higher returns, as Regeneron was not included in a recent top stock list.

Is Regeneron a Multimillionaire-Maker Stock?